Up-date on the NeoVitaA Trial: Obstacles, challenges, perspectives, and local experiences.
Wien Med Wochenschr
; 167(11-12): 264-270, 2017 Sep.
Article
em En
| MEDLINE
| ID: mdl-27671007
ABSTRACT
The aim of the NeoVitaA Trial is to assess the role of postnatal additional high-dose oral vitamin A supplementation for 28 days in reducing Bronchopulmonary dysplasia (BPD) or death in extremely low birth weight (ELBW) infants at 36 weeks postmenstrual age (PMA). All infants (both intervention and control group) will be provided with basic vitamin A (1000 IU/kg/day) in addition to trial intervention.In this short communication, we will give an up-date on obstacles, challenges as well as perspectives and potential solutions when putting into place a multicenter, double-blind, randomized trial in this cohort of extremely susceptible infants.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Vitamina A
/
Displasia Broncopulmonar
/
Recém-Nascido de Peso Extremamente Baixo ao Nascer
Tipo de estudo:
Clinical_trials
Limite:
Humans
/
Newborn
País/Região como assunto:
Europa
Idioma:
En
Revista:
Wien Med Wochenschr
Assunto da revista:
MEDICINA
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Alemanha